Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Priority
PNG
media_image1.png
18
296
media_image1.png
Greyscale
, is acknowledged.
Status of Claims
Claims 1-20 are currently pending in the application.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-8 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Choi et al (2004). Applicant claims pharmaceutical compositions comprising a compound of Formula (I) for use in reducing hyperpigmentation thereof. Choi et al (2014) also disclose pharmaceutical compositions comprising an identical stilbene compound for treating hyperpigmentation, which anticipates the instantly claimed inventions, wherein R1, R2, R3, R4 and R8 are hydrogen or hydroxyl [
PNG
media_image2.png
222
556
media_image2.png
Greyscale
, STN International, CAPLUS database, Accession Number 2004 : 970528, a copy is provided with this Office action].
Claims 1-8 are also rejected under 35 U.S.C. § 102(a)(2) as being anticipated by Zhang et al (US 10,188,590). Applicant claims pharmaceutical compositions comprising a compound of Formula (I) for use in reducing hyperpigmentation thereof. Zhang et al (US ‘590) also disclose similar skin-protection pharmaceutical compositions comprising compound and the method of uses thereof, which anticipate the instantly claimed inventions, wherein R1, R2, R3, R4 and R8 are hydrogen or hydroxyl [
PNG
media_image3.png
326
262
media_image3.png
Greyscale
, Claim 1, column 49-50, US ‘590].
Telephone Inquiry
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 7:30 AM - 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks, Ph.D. can be reached at (571) 270-7682.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.
/GOLAM M SHAMEEM/Primary Examiner, Art Unit 1621
Prosecution Insights